+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Arrhythmias (Cardiovascular) - Drugs In Development, 2021

  • ID: 5359584
  • Drug Pipelines
  • June 2021
  • Region: Global
  • 92 pages
  • Global Markets Direct

FEATURED COMPANIES

  • Aetas Pharma Co Ltd
  • Espero BioPharma Inc
  • Gilead Sciences Inc
  • Nissan Chemical Corp
  • Orion Corp
  • Stablix
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Summary

The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Arrhythmias (Cardiovascular) - Drugs In Development, 2021, provides an overview of the Arrhythmias (Cardiovascular) pipeline landscape.

An arrhythmia is a problem with the rate or rhythm of the heartbeat. During an arrhythmia, the heart can beat too fast, too slow, or with an irregular rhythm. Signs and symptoms include anxiety, weakness, dizziness, and light-headedness, fainting or nearly fainting, sweating, shortness of breath and chest pain. Treatment includes anti-arrhythmics and anticoagulants.

Report Highlights

The publisher's Pharmaceutical and Healthcare latest pipeline guide Arrhythmias (Cardiovascular) - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Arrhythmias (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Arrhythmias (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Arrhythmias and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 11 and 7 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 4 and 3 molecules, respectively.

Arrhythmias (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Arrhythmias (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Arrhythmias (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Arrhythmias (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Arrhythmias (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Arrhythmias (Cardiovascular)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Arrhythmias (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Arrhythmias (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Aetas Pharma Co Ltd
  • Espero BioPharma Inc
  • Gilead Sciences Inc
  • Nissan Chemical Corp
  • Orion Corp
  • Stablix
Introduction
  • Report Coverage
Arrhythmias - Overview

Arrhythmias - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
Arrhythmias - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
Arrhythmias - Companies Involved in Therapeutics Development
  • Academic Pharmaceuticals Inc
  • Aetas Pharma Co Ltd
  • Cardurion Pharmaceuticals LLC
  • Cynata Therapeutics Ltd
  • Espero BioPharma Inc
  • Galectin Therapeutics Inc
  • Gilead Sciences Inc
  • LATITUDE Pharmaceuticals Inc
  • Les Laboratoires Servier SAS
  • LQT Therapeutics Inc
  • Nissan Chemical Corp
  • OMEICOS Therapeutics GmbH
  • Orion Corp
  • SignPath Pharma Inc
  • Stablix
  • Vera Therapeutics Inc
Arrhythmias - Drug Profiles

amiodarone - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Antisense Oligonucleotides to Activate hERG1 for Arrhythmias - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
belapectin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
CYP-002 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
efsevin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
ESP-001 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Fusion Proteins for Arrhythmias - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
GS-680 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
KN-93 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
M-201 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
MC-450 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
NTC-801 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Oligonucleotides to Activate KCNH2 for Romano-Ward Syndrome - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
OMT-28 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
ORM-10103 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
ORM-11372 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
PP-1 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Recombinant Protein for Myocardial Infarction and Ventricular Arrhythmia - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Small Molecules 1 for Arrhythmia - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Small Molecules for Arrhythmia - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Small Molecules for Arrhythmias - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Small Molecules to Antagonize RyR2 for Heart Failure and Arrhythmias - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Small Molecules to Block KCa3.1 for Arrhythmias - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Small Molecules to Inhibit FKBP1A for Cardiovascular Diseases - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Small Molecules To Inhibit SGK-1 for Long QT Syndrome - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
soestelol - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
SPP-4040 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Arrhythmias - Dormant Projects

Arrhythmias - Discontinued Products

Arrhythmias - Product Development Milestones

Featured News & Press Releases
  • Oct 29, 2020: AnaBios and Orion publish scientific article describing novel cardiac compound
  • Sep 27, 2017: U.S. Patent Granted for Cynata Cymerus Technology
  • Sep 05, 2017: Cynata to Present at the 19th Annual Rodman & Renshaw Global Investment Conference in New York
  • Apr 19, 2017: Cynata Advances to Pre-IND Meeting with US FDA
Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Number of Products under Development for Arrhythmias, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Universities/Institutes, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Arrhythmias - Pipeline by Academic Pharmaceuticals Inc, 2021
  • Arrhythmias - Pipeline by Aetas Pharma Co Ltd, 2021
  • Arrhythmias - Pipeline by Cardurion Pharmaceuticals LLC, 2021
  • Arrhythmias - Pipeline by Cynata Therapeutics Ltd, 2021
  • Arrhythmias - Pipeline by Espero BioPharma Inc, 2021
  • Arrhythmias - Pipeline by Galectin Therapeutics Inc, 2021
  • Arrhythmias - Pipeline by Gilead Sciences Inc, 2021
  • Arrhythmias - Pipeline by LATITUDE Pharmaceuticals Inc, 2021
  • Arrhythmias - Pipeline by Les Laboratoires Servier SAS, 2021
  • Arrhythmias - Pipeline by LQT Therapeutics Inc, 2021
  • Arrhythmias - Pipeline by Nissan Chemical Corp, 2021
  • Arrhythmias - Pipeline by OMEICOS Therapeutics GmbH, 2021
  • Arrhythmias - Pipeline by Orion Corp, 2021
  • Arrhythmias - Pipeline by SignPath Pharma Inc, 2021
  • Arrhythmias - Pipeline by Stablix, 2021
  • Arrhythmias - Pipeline by Vera Therapeutics Inc, 2021
  • Arrhythmias - Dormant Projects, 2021
  • Arrhythmias - Discontinued Products, 2021
List of Figures
  • Number of Products under Development for Arrhythmias, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Number of Products by Top 10 Targets, 2021
  • Number of Products by Stage and Top 10 Targets, 2021
  • Number of Products by Top 10 Mechanism of Actions, 2021
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021
Note: Product cover images may vary from those shown
  • Academic Pharmaceuticals Inc
  • Aetas Pharma Co Ltd
  • Cardurion Pharmaceuticals LLC
  • Cynata Therapeutics Ltd
  • Espero BioPharma Inc
  • Galectin Therapeutics Inc
  • Gilead Sciences Inc
  • LATITUDE Pharmaceuticals Inc
  • Les Laboratoires Servier SAS
  • LQT Therapeutics Inc
  • Nissan Chemical Corp
  • OMEICOS Therapeutics GmbH
  • Orion Corp
  • SignPath Pharma Inc
  • Stablix
  • Vera Therapeutics Inc
Note: Product cover images may vary from those shown
Adroll
adroll